AR024391A1 - Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp - Google Patents

Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp

Info

Publication number
AR024391A1
AR024391A1 ARP000103012A ARP000103012A AR024391A1 AR 024391 A1 AR024391 A1 AR 024391A1 AR P000103012 A ARP000103012 A AR P000103012A AR P000103012 A ARP000103012 A AR P000103012A AR 024391 A1 AR024391 A1 AR 024391A1
Authority
AR
Argentina
Prior art keywords
increase
abc1
methods
compositions
cholesterol
Prior art date
Application number
ARP000103012A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR024391A1 publication Critical patent/AR024391A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invencion se refiere a polipéptidos de ABC1 novedosos y moléculas de ácido nucleico que los codifican. La invencion suministra vectores recombinantes, células huésped y composiciones farmacéuticas que comprenden los polinucleotidos deABC 1, como también a métodos para producir los polipéptidos de ABC1.La invencion además suministra métodos para el diagnostico, tratamiento, mejoramiento y/o prevencion de enfermedades asociadas con un flujo de salida decolesterol disminuido y/oHDL baj o. La presente invencion además suministra métodos para identificar los compuestos que modulan la expresion de ABC1 y métodospara detectar el nivel de polipéptidos y polinucleotidos de ABC1 en un sujeto mamífero. La presente invencion ademássuminist ra equipos y composicionesapropiadas para analizar los compuestos para determinar la actividad que modula la expresion de ABC1 del compuesto, como también los equipos y composicionesapropiados para determinar si el compuesto modula el flujode salida de colesterol que depende de ABC1.
ARP000103012A 1999-06-18 2000-06-16 Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp AR024391A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
AR024391A1 true AR024391A1 (es) 2002-10-02

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000103013A AR024576A1 (es) 1999-06-18 2000-06-16 Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp
ARP000103012A AR024391A1 (es) 1999-06-18 2000-06-16 Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP000103013A AR024576A1 (es) 1999-06-18 2000-06-16 Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp

Country Status (19)

Country Link
EP (2) EP1190065A2 (es)
JP (4) JP2003508031A (es)
KR (2) KR100476519B1 (es)
CN (2) CN1379817A (es)
AR (2) AR024576A1 (es)
AT (1) ATE422545T1 (es)
AU (3) AU777461B2 (es)
BR (2) BR0011753A (es)
CA (2) CA2375787C (es)
DE (1) DE60041545D1 (es)
HK (2) HK1046427A1 (es)
IL (2) IL147021A0 (es)
MX (2) MXPA01013174A (es)
NO (2) NO20016114L (es)
NZ (3) NZ531401A (es)
SG (2) SG121852A1 (es)
TR (2) TR200200441T2 (es)
TW (2) TWI304737B (es)
WO (2) WO2000078972A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1100895T1 (de) 1999-03-15 2001-09-06 The University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
AU6074700A (en) * 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
NZ522360A (en) 2000-05-02 2004-12-24 Aventis Pharma Sa Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002317093A1 (en) * 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
CA2463395A1 (en) * 2001-10-12 2003-04-24 Grelan Pharmaceutical Co., Ltd. Therapeutic agents for low hdl-cholesterolemia
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US6696473B2 (en) 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
RU2006105646A (ru) 2003-07-23 2007-09-10 Экселиксис, Инк. (Us) Производные азепина в качестве фармацевтических агентов
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
AU2006261845C1 (en) 2005-06-27 2013-05-16 Exelixis Patent Company Llc Imidazole based LXR modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2008062830A1 (fr) 2006-11-24 2008-05-29 Hykes Laboratories Llc Composé de spiroquinone et composition pharmaceutique
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
ES2610622T3 (es) * 2009-03-31 2017-04-28 The General Hospital Corporation Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
CA2761934C (en) 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
EA037063B1 (ru) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
US9834542B2 (en) 2013-03-15 2017-12-05 Bristo-Myers Squibb Company LXR modulators
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
TWI825021B (zh) 2017-06-02 2023-12-11 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
TWI802576B (zh) 2017-06-02 2023-05-21 德商馬克專利公司 與ａｄａｍｔｓ結合之免疫球蛋白
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522360A (en) * 2000-05-02 2004-12-24 Aventis Pharma Sa Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Also Published As

Publication number Publication date
IL147022A0 (en) 2002-08-14
EP1218515B1 (en) 2009-02-11
CA2375787A1 (en) 2000-12-28
CN1434865A (zh) 2003-08-06
AR024576A1 (es) 2002-10-16
BR0011696A (pt) 2002-04-30
CN1379817A (zh) 2002-11-13
WO2000078972A3 (en) 2002-05-02
NO20016114D0 (no) 2001-12-14
TWI259205B (en) 2006-08-01
HK1046708A1 (zh) 2003-01-24
CA2375787C (en) 2007-03-27
TW200626176A (en) 2006-08-01
SG121852A1 (en) 2006-05-26
TWI304737B (en) 2009-01-01
TR200200441T2 (tr) 2002-11-21
MXPA01013175A (es) 2002-06-04
NZ531401A (en) 2005-08-26
NZ516061A (en) 2004-04-30
ATE422545T1 (de) 2009-02-15
WO2000078971A2 (en) 2000-12-28
IL147021A0 (en) 2002-08-14
NO20016114L (no) 2002-02-12
AU2005200171A1 (en) 2005-02-10
JP2003506097A (ja) 2003-02-18
JP2005112859A (ja) 2005-04-28
DE60041545D1 (de) 2009-03-26
WO2000078972A9 (en) 2002-07-18
AU5743400A (en) 2001-01-09
KR20020012281A (ko) 2002-02-15
NO20016121D0 (no) 2001-12-14
EP1218515A2 (en) 2002-07-03
JP2003508031A (ja) 2003-03-04
EP1190065A2 (en) 2002-03-27
HK1046427A1 (zh) 2003-01-10
TR200200440T2 (tr) 2002-09-23
KR20020012612A (ko) 2002-02-16
CN100513570C (zh) 2009-07-15
AU5746700A (en) 2001-01-09
WO2000078972A2 (en) 2000-12-28
BR0011753A (pt) 2002-04-30
SG121853A1 (en) 2006-05-26
KR100476519B1 (ko) 2005-03-17
JP2006137750A (ja) 2006-06-01
MXPA01013174A (es) 2002-06-04
WO2000078971A3 (en) 2002-01-17
JP4277956B2 (ja) 2009-06-10
NZ529785A (en) 2005-09-30
AU777461B2 (en) 2004-10-14
NO20016121L (no) 2002-02-12
WO2000078972A8 (en) 2001-06-21
CA2375781A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
AR024391A1 (es) Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp
Jahngen et al. The eye lens has an active ubiquitin-protein conjugation system.
Williamson et al. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa (∗)
Coen et al. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
Freitag et al. Reversible methylation of cytoskeletal and membrane proteins in intact human erythrocytes.
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
Søe et al. Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication
Carceller et al. Perineuronal nets: subtle structures with large implications
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
Su et al. Labial stem cell extract mitigates injury to irradiated salivary glands
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
Chintalgattu et al. Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model
Tóth et al. Lacrimal preganglionic neurons form a subdivision of the superior salivatory nucleus of rat: transneuronal labelling by pseudorabies virus
Bradford et al. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
Szabo et al. Comparative salivary proteomics of cleft palate patients
DK1504261T3 (da) T celle subpopulation der regulerer tarmimmunitet
RU2001130755A (ru) Диагностика риска развития у субъекта атеросклероза или диабетической ретинопатии
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
ES2130629T3 (es) Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.
Chen et al. Developmental status of neurons selectively vulnerable to rapidly triggered post-ischemic caspase activation
Yamashita et al. Neuroprotection and neurosupplementation in ischaemic brain

Legal Events

Date Code Title Description
FB Suspension of granting procedure